iSpecimen (ISPC) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 declined 85% year-over-year to $156,009, driven by a 61% drop in specimen count and a 62% decrease in average selling price per specimen.

• Net loss widened to $2.28 million from $1.66 million in Q1 2025, reflecting lower sales and increased sales and marketing expenses.

• The company implemented significant cost reductions, including a 70% decrease in monthly compensation costs and a 36% reduction in technology costs compared to Q1 2025.

• Management continues to focus on operational streamlining, supplier network refresh, and a shift to high-value suppliers.

Financial highlights

• Revenue: $156,009 in Q1 2026, down from $1,057,510 in Q1 2025.

• Net loss: $2,275,221 in Q1 2026, compared to $1,658,396 in Q1 2025.

• Cash and cash equivalents: $2.82 million as of March 31, 2026, down from $6.88 million at year-end 2025.

• Working capital deficit: $2.12 million as of March 31, 2026.

• Operating expenses: $2.69 million in Q1 2026, flat year-over-year.

Outlook and guidance

• Management expresses substantial doubt about the company’s ability to continue as a going concern for the next year without additional capital or improved profitability.

• Plans include further cost containment, revenue enhancement projects, and potential capital raises.